1. Home
  2. |Insights
  3. |PODCAST: President Trump’s Early Trade Policy Moves – What it Means for Business — C&M’s First 100 Days Series

PODCAST: President Trump’s Early Trade Policy Moves – What it Means for Business — C&M’s First 100 Days Series

Client Alert | 1 min read | 02.03.17

As part of Crowell & Moring’s “First 100 Days” series, Paul Davies and Andrew Blasi of C&M International, Crowell & Moring’s international policy and regulatory affairs consulting affiliate, discuss the trade policy moves made so far by the Trump Administration, and what it means for businesses who are involved in trade issues. Paul is a director at C&M International and a former Australian trade negotiator. Andrew is an associate director at C&M International and a former staff member of the US-ASEAN Business Council and the U.S. House of Representatives.

Covered in this 16 minute podcast:

  • President Trump’s early trade policy emphasis on limiting imports and eliminating the trade deficit.
  • Implications of the U.S. withdrawal from TPP and the main takeaways for businesses.
  • The president’s upcoming meeting with Prime Minister Abe of Japan and where things stand.
  • Thoughts on NAFTA and what businesses might expect.

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...